Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | GCK | P35557 | 15/20 | 0.80 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2662844 | 1.00 | KCNH2 (1.00) | KCNH2GCKGAATHRBFFAR2 | |
| SCHEMBL2647237 | 1.00 | KCNH2 (1.00) | KCNH2GCKGAATHRBFFAR2 | |
| SCHEMBL2642219 | 0.92 | GCK (0.90) | KCNH2GCKGAATHRBFFAR2 | |
| SCHEMBL14423150 | 0.92 | GCK (0.90) | KCNH2GCKGAATHRBFFAR2 | |
| SCHEMBL2642181 | 0.92 | KCNH2 (0.85) | KCNH2GCK | |
| SCHEMBL2659254 | 0.92 | KCNH2 (0.85) | KCNH2GCK | |
| SCHEMBL14423123 | 0.92 | KCNH2 (0.85) | KCNH2GCK | |
| SCHEMBL14423121 | 0.91 | KCNH2 (0.83) | KCNH2GCKGAATHRBFFAR2 | |
| SCHEMBL2642052 | 0.91 | KCNH2 (0.83) | KCNH2GCKGAATHRBFFAR2 | |
| SCHEMBL14423152 | 0.90 | KCNH2 (0.81) | KCNH2GCKGAATHRBFFAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610846-B1 | Increase insulin secretion; type II diabetes; 2,3-Di-substituted N-heteroaromatic propionamides with 3- a phenyl group and 2- a methyl cycloalkyl ring; 3-cyclopentyl-2-(3,4-dichlorophenyl)-N-pyridazin-3-yl-propionamide | HOFFMAN-LA ROCHE INC. | 2003-08-26 | — | — | US | claimed |
| US-10961266-B2 | Chemoselective methylene hydroxylation in aromatic molecules | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200087331-A1 | CHEMOSELECTIVE METHYLENE HYDROXYLATION IN AROMATIC MOLECULES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2020-03-19 | — | — | US | disclosed |
| US-20070203207-A1 | Heteroaromatic glucokinase activators | BIZZARRO FRED T | 2007-08-30 | — | — | US | disclosed |
| US-20070203207-A1 | Heteroaromatic glucokinase activators | BIZZARRO FRED T | 2007-08-30 | — | — | US | disclosed |
| US-7223868-B2 | Such as 2-(3-chloro-phenyl)-3-cyclopentyl-N-thiazol-2-yl-propionamide which increases insulin secretion in treatment of type II diabetes | HOFFMANN-LA ROCHE INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223868-B2 | Such as 2-(3-chloro-phenyl)-3-cyclopentyl-N-thiazol-2-yl-propionamide which increases insulin secretion in treatment of type II diabetes | HOFFMANN-LA ROCHE INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050261503-A1 | Heteroaromatic glucokinase activators | BIZZARO FRED T | 2005-11-24 | — | — | US | disclosed |
| US-6951945-B2 | Heteroaromatic glucokinase activators | HOFFMAN-LA ROCHE INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-20040014968-A1 | Heteroaromatic glucokinase activators | BIZZARRO FRED THOMAS (US) | 2004-01-22 | — | — | US | disclosed |
| US-6610846-B1 | Increase insulin secretion; type II diabetes; 2,3-Di-substituted N-heteroaromatic propionamides with 3- a phenyl group and 2- a methyl cycloalkyl ring; 3-cyclopentyl-2-(3,4-dichlorophenyl)-N-pyridazin-3-yl-propionamide | HOFFMAN-LA ROCHE INC. | 2003-08-26 | — | — | US | disclosed |
| US-6610846-B1 | Increase insulin secretion; type II diabetes; 2,3-Di-substituted N-heteroaromatic propionamides with 3- a phenyl group and 2- a methyl cycloalkyl ring; 3-cyclopentyl-2-(3,4-dichlorophenyl)-N-pyridazin-3-yl-propionamide | HOFFMAN-LA ROCHE INC. | 2003-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014968-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | KCNH2 1022/4885GCK 2/4885GAA 589/4885 |
| US-10961266-B2 | Chemoselective methylene hydroxylation in aromatic molecules | PAH, DBH, AHR | KCNH2 814/4885GCK 2811/4885GAA 1030/4885 |
| US-20200087331-A1 | CHEMOSELECTIVE METHYLENE HYDROXYLATION IN AROMATIC MOLECULES | PAH, DBH, AHR | KCNH2 814/4885GCK 2811/4885GAA 1030/4885 |
| US-20070203207-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | KCNH2 1022/4885GCK 2/4885GAA 589/4885 |
| US-20050261503-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | KCNH2 1022/4885GCK 2/4885GAA 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.